stars 1 stars 2 stars 3

Maxonis is a biotechnology company developing LDP-916 (AGRG), a next-generation regenerative gel for Peripheral Nerve Injury (PNI) and Spinal Cord Injury (SCI). Based on 15+ years of research at Tel Aviv Sourasky Medical Center, LDP-916 uses four FDA-recognized materials to guide axonal regrowth and bridge long nerve gaps. Our mission is to deliver a minimally invasive, scalable, and clinically meaningful solution for true nerve regeneration.

Maxonis Questions

The Maxonis annual revenue was $1 million in 2026.

Itay Itzhaky is the CEO and Co-founder of Maxonis.

8 people are employed at Maxonis.

The NAICS codes for Maxonis are [54, 541].

The SIC codes for Maxonis are [73, 737].

Top Maxonis Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users